Literature DB >> 7901886

Persistent effects of (+/- )3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep.

R P Allen1, U D McCann, G A Ricaurte.   

Abstract

(+/- )3,4-methylenedioxymethamphetamine (MDMA) is a recreational drug of abuse which damages serotonin neurons in animals. It is not known whether MDMA is also neurotoxic in humans, and if so, whether there are functional consequences. Given the putative role of serotonin in sleep, it was hypothesized that one manifestation of serotonin neurotoxicity in humans might be disturbances of sleep. To determine whether MDMA use has effects on sleep, all-night polysomnograms of 23 MDMA users were compared to those of 22 age- and sex-matched controls. On average, MDMA users had 19 minutes less total sleep and 23.2 minutes less non-REM (NREM) sleep than controls. These statistically significant differences in NREM sleep were due primarily to an average of 37 minutes less stage 2 sleep, with no significant differences noted in stages 1, 3 or 4. Although it is not known whether the alterations in sleep observed in MDMA users are due to serotonin neurotoxicity, the present findings suggest that MDMA use can lead to persistent changes in CNS structures involved in human sleep generation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901886     DOI: 10.1093/sleep/16.6.560

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  18 in total

1.  Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls.

Authors:  Robin L Carhart-Harris; David J Nutt; Marcus R Munafo; David M Christmas; Sue J Wilson
Journal:  Psychopharmacology (Berl)       Date:  2009-07-08       Impact factor: 4.530

2.  ERP evidence suggests executive dysfunction in ecstasy polydrug users.

Authors:  C A Roberts; S H Fairclough; J E Fisk; F Tames; C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2013-03-27       Impact factor: 4.530

3.  Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).

Authors:  Lynn Taurah; Chris Chandler; Geoff Sanders
Journal:  Psychopharmacology (Berl)       Date:  2013-10-11       Impact factor: 4.530

Review 4.  Interactions between disordered sleep, post-traumatic stress disorder, and substance use disorders.

Authors:  Ryan Vandrey; Kimberly A Babson; Evan S Herrmann; Marcel O Bonn-Miller
Journal:  Int Rev Psychiatry       Date:  2014-04

5.  MDMA induces Per1, Per2 and c-fos gene expression in rat suprachiasmatic nuclei.

Authors:  Rowan P Ogeil; David J Kennaway; Mark D Salkeld; Shantha M W Rajaratnam; Jillian H Broadbear
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

6.  3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development.

Authors:  H W Broening; L L Morford; S L Inman-Wood; M Fukumura; C V Vorhees
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

Review 7.  Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').

Authors:  U D McCann; S O Slate; G A Ricaurte
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

8.  Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA.

Authors:  Brigitta Balogh; Eszter Molnar; Rita Jakus; Linda Quate; Henry J Olverman; Paul A T Kelly; Sandor Kantor; Gyorgy Bagdy
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

9.  Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.

Authors:  G A Ricaurte; U D McCann
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

10.  Effects of acute 3,4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: a preliminary study.

Authors:  Surilla Randall; Chris-Ellyn Johanson; Manuel Tancer; Timothy Roehrs
Journal:  Sleep       Date:  2009-11       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.